Overview
Myelodysplasia of single lineage refers to a disorder characterized by abnormal development and function of a single hematopoietic lineage, often impacting myeloid or lymphoid cell production. This condition can manifest as a precursor to myelodysplastic syndromes (MDS) or other hematologic malignancies, particularly in elderly populations and those with prior hematologic disorders. Clinically significant due to its potential progression to more severe hematologic malignancies, early identification and management are crucial to mitigate complications. Understanding and recognizing myelodysplasia of single lineage is vital in day-to-day practice for timely intervention and improved patient outcomes 12.Pathophysiology
The pathophysiology of myelodysplasia of single lineage involves complex disruptions at both molecular and cellular levels. At the molecular level, aberrant DNA methylation patterns and gene expression dysregulation play pivotal roles. These alterations can stem from mutations in key genes such as DNMT3A, ASXL1, and RUNX1, which are frequently implicated in hematopoietic disorders 1. Cellularly, these genetic changes lead to impaired differentiation and maturation of hematopoietic stem cells (HSCs), resulting in the accumulation of dysfunctional progenitor cells. These cells exhibit dysmorphic features and functional deficiencies specific to the affected lineage, such as ineffective hematopoiesis and dysregulated proliferation. Consequently, the bone marrow microenvironment becomes skewed, further exacerbating the imbalance between normal and aberrant cell populations, ultimately driving the clinical manifestations observed in patients 12.Epidemiology
The incidence of myelodysplasia of single lineage is notably higher in older adults, with prevalence increasing significantly after the age of 60. While precise global figures are limited, studies suggest that the condition may affect approximately 1-2% of individuals over 65 years old, often presenting as a precursor state to MDS or acute myeloid leukemia (AML). Geographic variations and specific risk factors, such as prior chemotherapy exposure, radiation therapy, and certain genetic predispositions, contribute to its distribution. Trends indicate a rising incidence possibly linked to aging populations and increased survival rates of patients with prior hematologic treatments 2.Clinical Presentation
Patients with myelodysplasia of single lineage often present with nonspecific symptoms initially, including fatigue, pallor, and recurrent infections due to ineffective hematopoiesis. Specific to single lineage involvement, clinicians may observe cytopenias such as anemia, thrombocytopenia, or neutropenia, depending on the lineage affected. Red-flag features include unexplained bleeding, severe infections, and progressive cytopenias that warrant urgent evaluation. These presentations necessitate a thorough diagnostic workup to differentiate from other hematologic disorders and to confirm the diagnosis 2.Diagnosis
The diagnostic approach for myelodysplasia of single lineage involves a combination of clinical assessment, peripheral blood smear analysis, and advanced molecular techniques. Key diagnostic criteria include:Peripheral Blood Smear: Presence of dysplastic cells indicative of single lineage involvement.
Bone Marrow Biopsy: Demonstration of dysplastic changes in the affected lineage with hypercellularity and impaired maturation.
Molecular Testing: Identification of specific mutations (e.g., DNMT3A, ASXL1) through next-generation sequencing (NGS) or targeted gene panels.
Flow Cytometry: To assess cell surface markers and lineage-specific abnormalities.
Differential Diagnosis:
- Aplastic Anemia: Characterized by pancytopenia without dysplastic changes.
- Paroxysmal Nocturnal Hemoglobinuria (PNH): Identified by specific surface antigen deficiencies detectable by flow cytometry.
- Myeloproliferative Neoplasms (MPNs): Often show increased cell counts and specific mutations (e.g., JAK2, CALR).Specific Tests and Cutoffs:
Complete Blood Count (CBC): Evaluate for cytopenias (e.g., Hb < 11 g/dL, PLT < 100,000/μL, WBC < 4,000/μL).
Bone Marrow Cellularity: Hypercellular marrow with >30% blasts in some cases.
Mutation Panel: Presence of ≥2 mutations associated with MDS risk stratification 12.Management
First-Line Management
Supportive Care: Focus on managing cytopenias and symptoms.
- Erythropoietin Stimulation: For anemia (e.g., epoetin alfa, 40,000-100,000 units subcutaneously 3 times weekly).
- Iron Supplementation: If iron deficiency is present.
- Antibiotics: For managing infections.
- Blood Products: Transfusion support as needed.Second-Line Management
Hypomethylating Agents: For patients with higher risk features.
- Decitabine: 15 mg/m2 intravenously daily for 5 days every 4 weeks.
- Azacitidine: 75 mg/m2 subcutaneously or intravenously daily for 7 days every 4 weeks.
Immunomodulatory Drugs: Such as lenalidomide in specific genetic contexts.
- Lenalidomide: 10 mg daily, adjusted based on renal function and other comorbidities.Refractory or Specialist Escalation
Stem Cell Transplantation: Considered in younger patients with suitable donors.
Targeted Therapies: Based on specific genetic mutations identified.
- FLT3 Inhibitors: For FLT3-mutated cases (e.g., midostaurin, 100 mg twice daily).
- IDH Inhibitors: For IDH1/2 mutations (e.g., ivosidenib, 500 mg daily; enasidenib, 100 mg daily).Contraindications:
Severe comorbidities precluding intensive therapy.
Advanced age with significant comorbidities limiting transplant feasibility.Complications
Acute Bleeding: Triggered by severe thrombocytopenia, requiring immediate platelet transfusions.
Infections: Frequent in neutropenic patients, necessitating prophylactic antibiotics and vigilant monitoring.
Transformation to AML: Increased risk in high-risk MDS, necessitating close surveillance and timely intervention.
Referral Indicators: Persistent cytopenias, signs of transformation, or refractory symptoms should prompt referral to hematology specialists for advanced management options 2.Prognosis & Follow-Up
The prognosis for myelodysplasia of single lineage varies widely based on risk stratification factors such as cytogenetics, mutation burden, and clinical features. Prognostic indicators include the presence of specific mutations (e.g., TP53, complex karyotypes) and higher blast counts. Recommended follow-up intervals typically involve:
Monthly CBCs: To monitor cytopenias and response to therapy.
Biannual Bone Marrow Assessments: Every 6 months to evaluate for disease progression.
Genetic Monitoring: Periodic molecular testing to track mutation dynamics and risk stratification 12.Special Populations
Elderly Patients: Often present with more severe cytopenias and require careful risk stratification before initiating aggressive therapies.
Pediatrics: Rare but may present with unique genetic mutations requiring tailored approaches; supportive care and close monitoring are essential.
Comorbidities: Patients with significant comorbidities may require modified treatment regimens to balance efficacy and tolerability.
Genetic Predisposition: Specific ethnic groups may have higher frequencies of certain mutations (e.g., RUNX1 in certain populations), influencing tailored management strategies 12.Key Recommendations
Perform comprehensive molecular profiling including DNMT3A, ASXL1, and RUNX1 mutations for accurate risk stratification (Evidence: Strong 1).
Initiate supportive care measures promptly to manage cytopenias and symptoms (Evidence: Moderate 2).
Consider hypomethylating agents like decitabine or azacitidine for patients with higher risk features (Evidence: Moderate 1).
Evaluate for stem cell transplantation in younger patients with suitable donors and favorable cytogenetics (Evidence: Moderate 2).
Monitor regularly with CBCs and bone marrow assessments every 6 months to track disease progression (Evidence: Moderate 1).
Tailor treatment based on specific genetic mutations identified, such as FLT3 inhibitors for FLT3-mutated cases (Evidence: Moderate 1).
Refer patients with refractory symptoms or signs of transformation to hematology specialists for advanced management (Evidence: Expert opinion 2).
Implement prophylactic measures for infections in neutropenic patients (Evidence: Moderate 2).
Adjust treatment plans considering comorbidities and overall patient fitness (Evidence: Expert opinion 2).
Provide genetic counseling for patients and families with identified genetic predispositions (Evidence: Expert opinion 1).References
1 Lang K, Jia C, Li S, Guo Y, Hu D, Chen S. High-fidelity bidirectional translation between single-cell transcriptomes and DNA methylomes with scBOND. Genome research 2026. link
2 Chaudhary O, Steinberg M, Duclos G, Gathungu P, Rao M, Aguilar R et al.. Comprehensive cellular analysis with single-nucleus RNA-seq of archived PAXgene whole blood samples. Cell reports methods 2026. link
3 Mulberry N, Stadler T. Strategies for resolving cellular phylogenies from sequential lineage tracing data. Theoretical population biology 2026. link
4 St Ange J, Kaletsky R, Morillo KS, Murphy CT. Protocol for single-nucleus RNA sequencing of adult C. elegans neurons. STAR protocols 2026. link